Lipei Liu

Key Laboratory Of Bioactive Materials Of Ministry Of Education
Changhongjie, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Nogo-B inhibition restricts ulcerative colitis via inhibiting p68/miR-155 signaling pathway.

Nogo-B inhibition restricts ulcerative colitis via inhibiting p68/miR-155 signaling pathway.

Journal: International immunopharmacology
Published: March 28, 2023

Test development, optimization and validation of a WGS pipeline for genetic disorders.

Test development, optimization and validation of a WGS pipeline for genetic disorders.

Journal: BMC medical genomics
Published: December 08, 2022

A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.

A novel therapy for hepatic cholestasis treatment-the combination of rosiglitazone and fenofibrate.

Journal: European journal of pharmacology
Published: August 03, 2022

Peroxisome Proliferator-Activated Receptor-Gamma Reduces ER Stress and Inflammation via Targeting NGBR Expression.

Peroxisome Proliferator-Activated Receptor-Gamma Reduces ER Stress and Inflammation via Targeting NGBR Expression.

Journal: Frontiers in pharmacology
Published: November 18, 2021

Whole Genome Sequencing in the Evaluation of Fetal Structural Anomalies: A Parallel Test with Chromosomal Microarray Plus Whole Exome Sequencing.

Whole Genome Sequencing in the Evaluation of Fetal Structural Anomalies: A Parallel Test with Chromosomal Microarray Plus Whole Exome Sequencing.

Journal: Genes
Published: January 05, 2021

Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis.

Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis.

Journal: British journal of pharmacology
Published: September 24, 2020

TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular smooth muscle cells.

TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular smooth muscle cells.

Journal: The Journal of biological chemistry
Published: August 04, 2020

ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway.

ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway.

Journal: Theranostics
Published: June 21, 2020

Food with calorie restriction reduces the development of atherosclerosis in apoE-deficient mice.

Food with calorie restriction reduces the development of atherosclerosis in apoE-deficient mice.

Journal: Biochemical and biophysical research communications
Published: December 28, 2019

Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.

Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.

Journal: Biochemical and biophysical research communications
Published: November 03, 2019

Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE-/- mice.

Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE-/- mice.

Journal: Theranostics
Published: July 03, 2019

Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice.

Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 11, 2019
Showing 1-12 of 21

Last Updated: 09/26/2026